drugset / Trial / NCT05158023
Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Phase 2b study designed to evaluate the efficacy and safety of ASLAN004 in adult patients with moderate-to-severe Atopic Dermatitis (AD) who are candidates for systemic therapy. This study will have 5 treatment arms (4 active and 1 placebo).
Timeline
- Start
- 2022-03-16
- Primary completion
- 2023-06-13
- Completion
- 2023-09-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ASLAN004 | Monoclonal antibody | 300 mg | Subcutaneous |
| Subject | ASLAN004 | Monoclonal antibody | 400 mg | Subcutaneous |
| Subject | ASLAN004 | Monoclonal antibody | 600 mg | Subcutaneous |